Skip to content

Royan Institute

  Home arrow Clinical Services arrow Cell Therapy Center arrow Neuromuscular Disorders
Neuromuscular Disorders PDF Print E-mail
In Neurology group, the researchers have tested the efficacy and safety of stem cell transplantation in multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and cerebral palsy. Eleven patients with cerebral palsy were enrolled in this study. It is showed that Intrathecal injections of bone marrow derived CD133 positive cells to these patients were safe and there were no significant adverse reaction. In addition, treated group, showed improvements in motor and cognitive functions to some extent in comparison to control group. Seven patients received a second injection of CD133 positive cells within 6 months and result of serial injection were compared to single injection in its efficacy in motor and cognitive functions improvement.

GMFM; Gross Motor Functional Measurement, FIM+FAM; Functional Independence Measure+
Functional Assessment Measure in patients who are treated with bone marrow derived CD133 cells (before, 0 and six months 6, after intrathecal injection)
Intravenous injection of bone marrow derived mesenchymal stem cells for patients with MS were evaluated in a controlled double blind clinical trial.
Patients are being evaluated with several tests including physical exam, serum biochemical markers and imaging. Safety and efficacy of intravenous, intrathecal and intraventricular injection of bone marrow derived mesenchymal stem cells (BM-MSC) for patients with ALS are being tested. Currently, six patients underwent intravenous transplantation.

Main Menu